Trial intelligence / Profile preview

Stepwise medical treatment of Cushing's disease

NL-OMON30660Recruiting

Sponsor
Erasmus MC
Start
Sep 2007
Modality
Small Molecules, Peptides
Countries
1
01

Overview

Open-label, single-arm trial of pasireotide LAR, cabergoline and ketoconazole in Corticotropin adenoma (ACTHoma), sponsored by Erasmus MC. Primary endpoint: Achievement of normocortisolism. Started Sep 2007; status: recruiting.

02

Drugs

pasireotide LARcabergolineketoconazole
03

Conditions

Corticotropin adenoma (ACTHoma)

Beyond the preview

Go deeper on NL-OMON30660.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON30660.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call